our participating thanks also today’s call. you, My who for and to in interest in investors Kamada analysts Thank and Bob. have
highly transition the months business six XXXX. fully global for the it of our GLASSIA by by encouraged diversified the market. our start into Let are me company is on I positive a our integrated outlook of our XXXX and performance to rest we the based a emphasizing sales and believe in to past in on commercial Takeda to the to plasma-derived a from ability dependency leader specialty testament rapidly year,
the progress we clinical program. leveraging key each new as our of categories, business, are as in well expanded distribution our in commercialization growth income in U.S., KEDRAB the U.S. critical territories, the in Israel, making royalty plasma our which Inhaled the U.S. of Importantly, our product immunoglobulin recently collection AAT include market, portfolio growth and GLASSIA
representing During the generated first X% half increase $XX.X of a we total revenue of XXXX million, year-over-year.
our EBITDA effective profitability validates multiple in cash million gain being full of business. of Strike, that and during portfolio the first adjusted adjusted we Our year the the increase to as The operations strong year markets acquired XXXX. last we sales delivered of almost Kamada quarter. traction position immunoglobulins million cash June $XX XX, a late of to second in and continues This generating FDA-approved excluding for loss could million of million $X.X representing operating the was EBITDA supported Labor our margin. associated which the XX% important six cash generated have It’s the been a $X $XX.X with and the flow, increase to note months
Kamada sales year-over-year. As in Inc. the received for proactive Currently we over with in approximately and responsible $XX a established collective margin, of already activities our in grow XX% is the new XXXX product. revenue portfolio million the of the revenues through acquired direct commercialization to gross significantly generated new promotion reminder, U.S., anticipate product the where subsidiary
XXXX. the in will this effort in this fruit marketing second begin the commencing bear year, U.S. expect half to We of
meaningful the already fourth signed this this to acquired supply Half outside $XX.X anticipated balance by to revenue portfolio and agreement seeing one extended product in principally agreement in to to million are markets. the half FDA newly undisclosed generated sales of strongly expected of be the the including international in also the to sales of recently VARIZIG, international the agreement America. validates of quarter four are the important of acquired This to XXXX. Latin first our of the North growth operating the organization be from approved America, market We products, international will an our year the ability supply grow commercial
encouraged transfer half to tech production effect and contrast the our to CYTOGAM, for new current which after nearly current at receipt we during are compared by are the territories assets. efforts of our key gross manufacturer. sourcing proactive higher should The the with through the leveraging in strategic commercial continue first also ahead strategic new ability of generate that now to Kamada’s approval We the us. shear of acquired largest facility in distribution opportunities the the through underscore commitment completion selling of leveraging relationship, pursue expect significant and add of as CYTOGAM facility compete. a of These own future the to FDA four margin contract continuing our from additional agreements are activities I supply XXXX, of Israeli to our products the
key half the the and by during second agreement, by for Kedrion, continued growth including VARIZIG new year supporting portfolio, sales to the factors, of sales outlook growth IgG stronger in-market new of multiple boosted expected the driven sales supply continued the XXXX. product anticipated including KEDRAB is of increased Our
to quarters of months royalty full in the half in income, two compared revenues the only first year total the the of addition, year. as GLASSIA four of will include half second In
remainder the continue royalties XX% Based KEDRAB gross the Moreover, million, on impact XX%. margins are EBITDA. driven promising with to $XXX reiterating now will of to and foreseeable be XXXX the our $XXX the half a Moreover, we the on This the substantially Strike first XX% concluded revenue, new XXXX EBITDA revenue half outlook than profitability profitability will continue compared XX% in rate half. growth of profit. a guidance more second million which to and year, the the of and our for products to a are the Second all IgG to represents revenue year year to generate X.Xx than pure XXXX as expected guidance GLASSIA which of projects have between double-digit we full margins increase XX% of ahead. years reduced Labor more by at sales, of
the to in that discuss collective other an continue be Strike concluded withdraw an mention while of business, the will recently I execution of agreement the availability of parties of markets. was our year through be effective international XXXX, of significance, after end I economic This the the years Before agreement. legally four new first in with at Labor the strike impact in Of prospects negotiated agreement. XX products terms by the may researching had facility on certain no Israel our will our
results Plasma However, discuss like the the negatively Kamada the second associated one-time quarter will Plasma, loss this Israeli based collection would to by at which shortly. financial as indicated, impacted discuss, Chaime U.S. were previous plant, the further of work I company’s with now company. stoppage our effect
a into U.S. remain represented plasma company. Kamada’s Our fully collection our specialty center entry market early plasma expanding the We center acquisition product supply additional continue on XXXX hyperimmune collection in at our integrated and the specialty of plans of supported further strategic to advance to and regular our to and this capacity focused plasma. collection the centers U.S. open plasma enhance of the plasma becoming goal
by Our and process be construction the finalization site selection for second startup to will second in activities center collection this half of followed is a close year. and we
We also third a for to by activities year-end. intend required initiate the center
expected enhance various the our markets, growth collection IgG capabilities our supply continued chain. is and plant strengthen As to boost in competitive a of reminder, our revenue plasma expansion position
important pre-COVID be the continued to trend half U.S., driver KEDRAB, an in the gain increasingly $XXX product pandemic Moving million next to KEDRAB in for continues COVID believe encouraged the comparison of it level. first in to which by are to market. moderation the and in sales sales years, us pandemic continue the Based as market we will this Kedrion year, few our We grew over the during growth immunoglobulin. U.S the expect share of the significantly rabies by on highly market on
a expect sales. GLASSIA on income royalty We
Kamada The from of second for X clinical an the of royalty program, recently million, quarter represented meeting let’s products. prior Phase evaluating pivotal clinical is inhaled to ongoing the revenue the Royalty received around and first deficiency. full efficacy treatment now the income of sales in-house for trial our and for which safety guidance. quarter product AAT AAT was quarter our we $X.X that InnovAATe turn innovative expanded AAT our With that, expectation this second
patients months, recruitment European few past the Over and traditional at began sites. screening
involvement with rate study. pleased current the are of We this in
our the trial in call, last and quarter, said Safety Monitoring continued To-date have of modification. the Data reported. no patients adverse series second no without Board events we prematurely discontinued in treatment drug-related been have Independent the As recommended
with exists As the study data substantial are To the FDA expected unified trial’s EMA. for as to is the regulatory said the for we a reminder, previously, both this a reiterate, qualify opportunity submissions and stride. in and be growing Inhaled $X the and to annual in we these U.S are is sales steadily billion transformation advance already excited in to product market and a AAT that Europe over the further what
a a Investor our emphasize and closing, the segment we like business of this so, dramatic revenues as understanding portfolio previously, upon we you just Israeli June, that achievable anticipated current XX transformation the Israel the encourage over biosimilar to of of launch XXXX. our done products within anticipated products product highlight million. has to peak our catalyst. you In I to more on have several we can not I’d the Day in addition The approval. review product our anticipated already months. will successful several of annual Collectively, so gain accomplished than $XX to sales. Moving material deeper are intend distribution to of launch years growth segment, of sales This this Analyst that state If through are said to hosted be in we regulatory virtual launched expected Distribution an
Moving on growth to forward, drive fronts, and ahead. all in we years strategy catalyst have our to continue the double-digit corporate on we execute the appropriate believe
with multiple our of about call the leader our over positioned Kamada specialty excited for Chaime of value milestones. creating I'll second growth plasma With results. his the is industry, quarter are We turn a now for as global XXXX financial upcoming to as please. review that, Chaime, in uniquely prospects
